Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GUSTAVO F WESTIN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1942588918
CMS profile
817217
Location
FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,622.50

164 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,605.28 163
Education $17.22 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GUSTAVO F WESTIN

NPI 1942588918 · CMS profile ID 817217

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

FORT MYERS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942588918?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942588918?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942588918?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GUSTAVO F WESTIN, NPI 1942588918, CMS profile ID 817217, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 164 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1942588918?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

164 matching records · $3,622.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 164 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 164.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $15.2609/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225893999 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.7809/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223906803 CMS
ABBVIE INC. $17.2509/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730559 CMS
BeOne Medicines USA, Inc. $28.7509/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202899686 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.4909/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222858261 CMS
Sumitomo Pharma America, Inc. $23.7409/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176735664 CMS
E.R. Squibb & Sons, L.L.C. $20.0208/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184546679 CMS
Incyte Corporation $16.8008/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226013287 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.0908/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222858257 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.6108/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225893996 CMS
Merck Sharp & Dohme LLC $26.1208/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238280829 CMS
Alexion Pharmaceuticals, Inc. $18.4708/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202934116 CMS
E.R. Squibb & Sons, L.L.C. $20.0508/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184546671 CMS
Geron Corporation $22.3608/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238896027 CMS
Sumitomo Pharma America, Inc. $14.7508/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1176735662 CMS
Janssen Biotech, Inc. $18.7508/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1175083295 CMS
PFIZER INC. $32.9608/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231688352 CMS
AstraZeneca Pharmaceuticals LP $24.5408/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206239821 CMS
ABBVIE INC. $9.4807/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730556 CMS
Celgene Corporation $30.5307/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184546665 CMS
Eisai Inc. $22.8407/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244481564 CMS
PharmaEssentia USA Corporation $20.8507/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246830992 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.8607/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222858252 CMS
PFIZER INC. $26.0707/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229124288 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.7607/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223901158 CMS
AstraZeneca Pharmaceuticals LP $24.2107/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206799787 CMS
BeOne Medicines USA, Inc. $17.9007/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202899672 CMS
Celgene Corporation $18.5007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184546655 CMS
Novartis Pharmaceuticals Corporation $24.6007/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200408174 CMS
ABBVIE INC. $18.0207/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730553 CMS
BeOne Medicines USA, Inc. $10.4807/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202899674 CMS
AstraZeneca Pharmaceuticals LP $25.1006/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206856827 CMS
PFIZER INC. $15.0806/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231577578 CMS
Exelixis Inc. $22.1806/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218794743 CMS
Daiichi Sankyo Inc. $26.9406/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1197083541 CMS
PUMA BIOTECHNOLOGY, INC. $16.8106/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251742852 CMS
Merck Sharp & Dohme LLC $33.3806/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238089627 CMS
Merck Sharp & Dohme LLC $20.5206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238279113 CMS
Merck Sharp & Dohme LLC $24.0506/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238323870 CMS
PUMA BIOTECHNOLOGY, INC. $15.5406/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251742122 CMS
ABBVIE INC. $23.6406/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730549 CMS
Merck Sharp & Dohme LLC $25.8206/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238140338 CMS
Alexion Pharmaceuticals, Inc. $20.1006/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202939134 CMS
Merck Sharp & Dohme LLC $25.0106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238089629 CMS
ABBVIE INC. $29.2806/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730546 CMS
Merck Sharp & Dohme LLC $24.8006/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238187098 CMS
BeOne Medicines USA, Inc. $15.2705/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202899676 CMS
Celgene Corporation $22.2005/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184546647 CMS
ABBVIE INC. $22.2805/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204730542 CMS
BeOne Medicines USA, Inc. $5.7205/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202899678 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,105.72 119
PY2020 $1,586.79 89
PY2021 $3,620.04 156
PY2022 $5,399.43 179
PY2023 $3,399.21 150
PY2024 $2,856.15 124
PY2025 $3,622.50 164

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $86,652.91 32
PY2023 Principal investigator $172,884.33 33
PY2022 Principal investigator $69,979.32 11
PY2021 Principal investigator $57,884.30 5
PY2020 Principal investigator $14,500.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,983.25 12/20/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082450854
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447574
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 12/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082447576
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,650.00 12/02/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082446510
Principal investigator 1 Genentech, Inc. $3,500.00 11/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463552
Principal investigator 1 Genentech, Inc. $251.00 10/21/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $421.20 09/09/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,107.96 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,718.55 09/04/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082436084
Principal investigator 1 Mirati Therapeutics, Inc. $5,823.90 08/23/2024 Non-covered Recipient Entity
University Cancer And Blood Center
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1124763912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,064.38 08/05/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082433262
Principal investigator 1 Genentech, Inc. $1,794.00 07/23/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,700.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,600.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/03/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082430968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428628
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428630
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428632
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,599.68 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428650
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428652
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,461.05 06/10/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082428654
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,492.35 04/01/2024 Non-covered Recipient Entity
University Cancer And Blood Center LLC-Bldg 700
Ph. I Brigimadlin+ ezabenlimab (BI 754091/PD-1 mAb) No dispute reported 06/30/2026 1101067745
Principal investigator 1 Mirati Therapeutics, Inc. $5,823.90 03/25/2024 Non-covered Recipient Entity
University Cancer And Blood Center
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1124763914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $187.89 03/25/2024 Non-covered Recipient Entity
UNIVERSITY CANCER & BLOOD CENTER LLC
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1082422159
Principal investigator 1 Genentech, Inc. $1,004.00 02/27/2024 Non-covered Recipient Entity
UNIVERSITY CANCER AND BLOOD CENTER LLC
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 1133463557
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,853.50 01/25/2024 Non-covered Recipient Entity
University Cancer And Blood Center LLC-Bldg 700
Ph. I Brigimadlin+ ezabenlimab (BI 754091/PD-1 mAb) No dispute reported 06/30/2026 1101069103